Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Rocuronium Bromide Injection Obtains Drug Registration Certificate.
Jianniu Corporation (603707.SH) announced that the company recently received the approval for Rocuronium Bromide issued by the National Medical Products Administration.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company has recently received the drug registration certificate for Rocuronium Bromide Injection 5ml:50mg and 10ml:100mg issued by the National Medical Products Administration.
Rocuronium Bromide Injection is used as an adjuvant for general anesthesia, to facilitate tracheal intubation during routine induction of anesthesia, and to maintain neuromuscular blockade of skeletal muscles during surgery.
Related Articles
Beijing Jiuka Health Care (00648) to resume trading on November 4th.
SICC Co.,Ltd. (02631): Wang Junguo was elected as a staff representative director.
On October 31st, IH Retail (01373) spent HK$118,500 to repurchase 150,000 shares.
Beijing Jiuka Health Care (00648) to resume trading on November 4th.
SICC Co.,Ltd. (02631): Wang Junguo was elected as a staff representative director.
On October 31st, IH Retail (01373) spent HK$118,500 to repurchase 150,000 shares.
RECOMMEND
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025
Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025
Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025
